The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The Neurotoxicant, Cuprizone, as a Model to Study Demyelination and Remyelination in the Central Nervous System
Open accessAbstract
Myelin of the adult CNS is vulnerable to a variety of metabolic, toxic, and autoimmune insults. That remyelination can ensue, following demyelinating insult, has been well demonstrated. Details of the process of remyelination are, however difficult to ascertain since in most experimental models of demyelination/remyelination the severity, localization of lesion site, or time course of the pathophysiology is variable from animal to animal. In contrast, an experimental model in which massive demyelination can be reproducibly induced in large areas of mouse brain is exposure to the copper chelator, cuprizone, in the diet. We review work from several laboratories over the past 3 decades, with emphasis on our own recent studies, which suggest an overall picture of cellular events involved in demyelination/remyelination. When 8 week old C57BL/6 mice are fed 0.2% cuprizone in the diet, mature olidgodendroglia are specifically insulted (cannot fulfill the metabolic demand of support of vast amounts of myelin) and go through apoptosis.This is closely followed by recruitment of microglia and phagoctytosis of myelin. Studies of myelin gene expression, coordinated with morphological studies, indicate that even in the face of continued metabolic challenge, oligodendroglial progenitor cells proliferate and invade demyelinated areas. If the cuprizone challenge is terminated, an almost complete remyelination takes place in a matter of weeks. Communication between different cell types by soluble factors may be inferred. This material is presented in the context of a model compatible with present data—and which can be tested more rigorously with the cuprizone model. The reproducibility of the model indicates that it may allow for testing of manipulations (e.g. available knockouts or transgenics on the common genetic background, or pharmacological treatments) which may accelerate or repress the process of demyelination and or remyelination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The C57BL/6 mice showed a dramatic loss of myelin staining at this time point (Fig. 1b), which is consistent with previous reports [5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon treatment with cuprizone, mice typically exhibit profound demyelination in the corpus callosum, the cortex and the superior cerebellar peduncles [4, 5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most investigators use the standard C57BL/6 mouse strain in the cuprizone model to study the different molecular components involved in the complex pathogenic processes leading to corpus callosum demyelination [5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the corpus callosum, apoptosis of oligodendrocytes is observed, together with recruitment of microglia/macrophages, astrocytes and oligodendrocyte progenitor cells (OPCs) [5, 6].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, the continuous exposure of C57BL/6 mice to cuprizone results in a pattern of two cycles of demyelination and remyelination, followed by chronic demyelination from which animals do not recover 36, 39.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, C57BL/6 mice experience a spontaneous partial remyelination after 6 weeks and then continue to demyelinate further when exposed continuously to cuprizone 36, 39.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, unlike microglia and astrocytes in C57BL/6 mice that respond vigorously to demyelination 2, 23, 39, these cell types in SJL mice have a guarded response at midline and in the lateral region, which correlates with subdued demyelination.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cuprizone toxicity produces profound demyelination in the white and grey matter of the brain that mirrors sites of MS pathology [46].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other features common to both cuprizone-induced and type 3 MS lesions are mitochondrial stress, selective loss of myelin-associated glycoprotein (MAG), lesions with indistinct borders that are not perivascular, pronounced glial activation, and lymphocyte infiltration [43, 46, 65, 69–71].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The histopathological hallmark of the cuprizone model as standardized by Hiremath is oligodendrocyte death and subsequent demyelination in the corpus callosum, superior cerebellar peduncles, hippocampus [42, 46–54] and several other areas of the mouse brain (reviewed in [20]).”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglial activation and axonal loss positively correlate with demyelination and the reproducible lesion localization – primarily in the corpus callosum [186], cerebellar peduncle [186], hippocampus [187], and cortex [184, 185, 188] – mirrors the topographical specificity of MS pathology, including subpial cortical demyelination seen in PMS patients.”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remyelination is very robust in the cuprizone model and starts directly after demyelination is complete, irrespective if cuprizone is further fed or not (Matsushima and Morell, 2001; Hiremath et al., 2008; Gudi et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depletion of microglia likewise prevented the loss of oligodendrocytes (OLs) in the CC that normally results from CUP treatment (Matsushima & Morell, 2001).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Matsushima & Morell, 2001
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The cuprizone model involves administration of the toxin cuprizone to induce oligodendrocyte apoptosis [4, 5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Here, we explored the effect of antibody-mediated TREM2 activation on microglia in a well-established toxin-induced model of demyelination in the CNS resulting from exposure to the copper chelator cuprizone (CPZ) in the diet [31].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“These events lead to OPC recruitment, differentiation into mature OLs, and then remyelination which is almost complete within few weeks from toxin withdrawal [31].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [31]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It may suggest that NODDI could be sensitive biomarkers to probe the different stages of white matter pathology between acute demyelination and chronic demyelination (Matsushima and Morell 2001).”
From Neurite orientation dispersion and density imaging of mouse brain microstructure (2019) · cites this paper as Matsushima and Morell 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Historically these cells are not linked to demyelination following cuprizone treatment because the loss of the V(D)J recombination activation gene-1 (RAG-1), which is critical for B- and T- lymphocyte generation [269], does not alter demyelination and T-cell accumulation in the corpus callosum [46, 270].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Demyelination peaks between 4.5 and 5 weeks of cuprizone exposure in the CC and between 5 and 6 weeks in the cortex and hippocampus (Hiremath et al., 1998; Matsushima and Morell, 2001; Skripuletz et al., 2008; Gudi et al., 2009; Koutsoudaki et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Strong astrogliosis comprising hypertrophy and hyperplasia of astrocytes occurs as a response to cuprizone treatment in different white and gray matter structures for instance the CC (Matsushima and Morell, 2001; Gudi et al., 2009), hippocampus, (Koutsoudaki et al., 2009; Norkute et al., 2009), cerebellum, cortex (Skripuletz et al., 2008), and basal ganglia (Pott et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Astrogliosis is an additional pathological hallmark of CUP treatment (Matsushima & Morell, 2001).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Matsushima & Morell, 2001
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice
Hiremath, M. M., Saito, Y., Knapp, G. W., Ting, J. P.-Y., Suzuki, K., & Matsushima, G. K. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00168-4 · Cited by 412
Self-citation(1978) · PubMed · Cited by 297
Nishiyama, A., Lin, X., Giese, N. A., Heldin, C., & Stallcup, W. B. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19960201)43:3 · Cited by 244
Insulin-Like Growth Factor-1 Inhibits Mature Oligodendrocyte Apoptosis during Primary Demyelination
Mason, J. L., Ye, P., Suzuki, K., D'Ercole, A. J., & Matsushima, G. K. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05703.2000 · Cited by 237
Self-citationKomoly, S., Hudson, L. D., Webster, H. D., & Bondy, C. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1894 · Cited by 223
Blakemore, W. F. (1972) · Journal of Neurocytology · doi:10.1007/bf01102943 · Cited by 217
Gene Expression in Brain during Cuprizone-Induced Demyelination and Remyelination
Morell, P., Barrett, C. V., Mason, J. L., Toews, A. D., Hostettler, J. D., Knapp, G. W., & Matsushima, G. K. (1998) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1998.0715 · Cited by 213
Self-citationDemyelination of the superior cerebellar peduncle in the mouse induced by cuprizone
Blakemore, W. F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90118-4 · Cited by 207
Blakemore, W. F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90119-6 · Cited by 177
Research works printed but not linked: 2
- Jurevics HA, 2000, Lipid metabolism during remyelination in brain, J Neurochem, 74, S32
- Ludwin SK, 1980, Chronic demyelination inhibits remyelination in the central nervous system, Lab Invest, 43, 382
Cited by
Sorted by citations
Items 601–700 of 985
Miyamura, S., Matsuo, N., Nagayasu, K., Shirakawa, H., & Kaneko, S. (2019) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3453 · Cited by 16
Hashem, M., Shafqat, Q., Wu, Y., Rho, J. M., & Dunn, J. F. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.118935 · Cited by 19
Teriflunomide as a therapeutic means for myelin repair
Göttle, P., Groh, J., Reiche, L., Gruchot, J., Rychlik, N., Werner, L., Agrelo, I. S., Akkermann, R., Zink, A., Prigione, A., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02686-6 · Cited by 16
Crocker, S. J., Bajpai, R., Moore, C. S., Frausto, R. F., Brown, G. D., Pagarigan, R. R., Whitton, J. L., & Terskikh, A. V. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01165.x · Cited by 16
Yan, G., Xuan, Y., Dai, Z., Shen, Z., Zhang, G., Xu, H., & Wu, R. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1464-2 · Cited by 18
Millet, V., Moiola, C. P., Pasquini, J. M., Soto, E. F., & Pasquini, L. A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.005 · Cited by 16
Puma, but not noxa is essential for oligodendroglial cell death
Hagemeier, K., Lürbke, A., Hucke, S., Albrecht, S., Preisner, A., Klassen, E., Hoffmann, E., Cui, Q., Antel, J. P., Brück, W., et al. (2013) · Glia · doi:10.1002/glia.22552 · Cited by 16
Mechanisms Involved in the Remyelinating Effect of Sildenafil
Lucena, D. D., Gutièrrez‐Mecinas, M., Moreno, B., Sánchez, J. L. M., Pifarré, P., & Garcı́a, A. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-017-9756-3 · Cited by 16
Olig2 Silence Ameliorates Cuprizone-Induced Schizophrenia-Like Symptoms in Mice
Liu, H., Zhai, J., Wang, B., & Fang, M. (2017) · Medical Science Monitor · doi:10.12659/msm.903842 · Cited by 16
Zhang, J., Yang, L., Fang, Z., Kong, J., Huang, Q., & Xu, H. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9799-0 · Cited by 16
Ultrahigh field imaging of myelin disease models: Toward specific markers of myelin integrity?
Petiet, A., Adanyeguh, I. M., Aigrot, M., Poirion, É., Nait‐Oumesmar, B., Santin, M. D., & Stankoff, B. (2018) · The Journal of Comparative Neurology · doi:10.1002/cne.24598 · Cited by 19
Cryptic Axonal Antigens and Axonal Loss in Multiple Sclerosis
DeVries, G. H. (2004) · Neurochemical Research · doi:10.1007/s11064-004-6873-1 · Cited by 15
ElKasabgy, N. A., Salama, A., & Salama, A. H. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104064 · Cited by 15
Hilton, J. B. W., Kysenius, K., Liddell, J. R., Mercer, S. W., Hare, D. J., Buncic, G., Paul, B. T., Wang, Y., Murray, S. S., Kilpatrick, T. J., et al. (2024) · Metallomics · doi:10.1093/mtomcs/mfad072 · Cited by 15
Omotoso, G. O., Olajide, O. J., Gbadamosi, I., Rasheed, M. A., & Izuogu, C. T. (2018) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2018.25.2.6 · Cited by 15
Effects of enhanced environment and induced depression on cuprizone mouse model of demyelination
Mohamed, A. S., Al‐Kafaji, G., Almahroos, A., Al-Mosawi, Z. M., Alalwan, H. F., Abdulla, R., Alammadi, F., Almubarak, A., Al-Mahrezi, A., & Kamal, A. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7654 · Cited by 15
Implication of Contactins in Demyelinating Pathologies
Kalafatakis, I., Savvaki, M., Velona, T., & Karagogeos, D. (2021) · Life · doi:10.3390/life11010051 · Cited by 16
Mancini, V. S. B. W., Pietro, A. A. D., de Olmos, S., Pinto, P. S., Vence, M., Marder, M., Igaz, L. M., Marcora, M. S., Pasquini, J. M., Correale, J. D., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15566 · Cited by 16
Remyelination by Endogenous Glia
Franklin, R. J. M., & Goldman, J. E. (2004) · Elsevier eBooks · doi:10.1016/b978-012439510-7/50060-7 · Cited by 15
TNFα: kill or cure for demyelinating disease?
Finsen, B. R., Antel, J. P., & Owens, T. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001120 · Cited by 15
Palavra, F., Viana, S. D., Henriques, S., Dinis, J., Martins, J., Madeira, M. H., Santiago, R., Petrella, L., Sereno, J., Castelo-Branco, M., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103886 · Cited by 14
Brain region dependent molecular signatures and myelin repair following chronic demyelination
Samtani, G., Kim, S.-J., Michaud, D., Hillhouse, A., Szule, J. A., Konganti, K., & Li, J. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1169786 · Cited by 16
Human iPSC ‐derived endothelial cells promote CNS remyelination via BDNF and mTORC1 pathway
Ma, D., Zhang, H., Yin, L., Xu, H., Wu, L., Shaji, R., Rezai, F., Mulla, A., Kaur, S., Tan, S., et al. (2023) · Glia · doi:10.1002/glia.24466 · Cited by 16
Rezapour-Firouzi, S., Mohammadian, M., Sadeghzadeh, M., & Mazloomi, E. (2020) · Gene · doi:10.1016/j.gene.2020.144987 · Cited by 14
Honarvar, F., Hojati, V., Zare, L., Bakhtiari, N., & Javan, M. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02059-x · Cited by 14
Diffusion tensor imaging of white matter pathology in the mouse brain
Zhang, J. (2010) · Imaging in Medicine · doi:10.2217/iim.10.60 · Cited by 16
Dasgupta, S., & Ray, S. K. (2018) · Therapeutic Targets for Neurological Diseases · doi:10.14800/ttnd.1598 · Cited by 14
Label-free assessment of myelin status using birefringence microscopy
Morgan, M. L., Brideau, C., Teo, W., Caprariello, A. V., & Stys, P. K. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109226 · Cited by 14
Oligodendroglioma and multiple sclerosis. A case report
de la Lama, A., Gómez, P. A., Rodríguez-Boto, G., Lagares, A., Alén, J. F., Lobato, R. D., & Ricoy, J. R. (2004) · Neurocirugía · doi:10.1016/s1130-1473(04)70473-x · Cited by 14
Understanding the spectrum of non-motor symptoms in multiple sclerosis
Weerasinghe-Mudiyanselage, P. D. E., Kim, J., Shin, T., & Moon, C. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.375307 · Cited by 13
An Association of Chitinase-3 Like-Protein-1 With Neuronal Deterioration in Multiple Sclerosis
Ahmad, I., Wergeland, S., Oveland, E., & Bø, L. (2023) · ASN NEURO · doi:10.1177/17590914231198980 · Cited by 13
Sajrawi, C., Odeh, M., Tiwari, A. K., Agranovich, B., Abramovich, I., Zubedat, S., Saar, G., Shaulov, L., Avital, A., Reznik, D., et al. (2024) · Glia · doi:10.1002/glia.24624 · Cited by 13
Jankovska, E., Lipcseyová, D., Svrdlikova, M., Pavelcová, M., Havrdová, E., Holada, K., & Petrák, J. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1837801 · Cited by 14
Cong, H., Liang, M., Wang, Y., Chang, H., Du, L., Zhang, X., & Yin, L. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.07.010 · Cited by 12
Anastasiadou, S., Liebenehm, S., Sinske, D., zu Reckendorf, C. M., Moepps, B., Nordheim, A., & Knöll, B. (2015) · Glia · doi:10.1002/glia.22794 · Cited by 13
Unconventional Myosin ID is Involved in Remyelination After Cuprizone-Induced Demyelination
Yamazaki, R., Baba, H., & Yamaguchi, Y. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2413-7 · Cited by 14
Shimizu, Y., Ishikawa, M., Gotoh, M., Fukasawa, K., Yamamoto, S., Iwasa, K., Yoshikawa, K., & Murakami‐Murofushi, K. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.01.002 · Cited by 13
Mohammadzadeh, A., Rezapour-Firouzi, S., Shahabi, S., Tehrani, A. A., Kheradmand, F., & Mazloomi, E. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.245964 · Cited by 13
Long lasting behavioural effects on cuprizone fed mice after neurotoxicant withdrawal
Tomàs-Roig, J., Torrente, M., Cabré, M., Vilella, E., & Colomina, M. T. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.01.036 · Cited by 15
Atkinson, K. C., Lee, J. B., Hasselmann, J., Kim, S. H., Drew, A., Soto, J. S., Katzenellenbogen, J. A., Harris, N. G., Obenaus, A., & Tiwari-Woodruff, S. K. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104501 · Cited by 13
Luo, F., Zhang, Z., Barnett, A., Bellinger, T. J., Turcato, F. C., Schmidt, K., & Luo, Y. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113168 · Cited by 12
Expression of retinoid X receptor beta is induced in astrocytes during corpus callosum demyelination
König, R., Stillfried, M., Aperdannier, P., Clarner, T., Beyer, C., Kipp, M., & Mey, J. (2012) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2012.01.002 · Cited by 13
Urbach‐Ross, D., & Kusnecov, A. W. (2007) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2007.03.010 · Cited by 13
Impairment of heme synthesis in myelin as potential trigger of multiple sclerosis
Morelli, A. M., Ravera, S., Calzia, D., & Panfoli, I. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.02.015 · Cited by 13
Millet, V., Marder, M., & Pasquini, L. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.11.028 · Cited by 15
Testosterone and Myelin Regeneration in the Central Nervous System
Schumacher, M., Ghoumari, A. M., Mattern, C., Bougneres, P. F., & Traiffort, É. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0023 · Cited by 14
p38γ MAPK delays myelination and remyelination and is abundant in multiple sclerosis lesions
Marziali, L. N., Hwang, Y., Palmisano, M., Cuenda, A., Sim, F. J., Gonzalez, A., Volsko, C. M., Dutta, R., Trapp, B. D., Wrabetz, L. G., et al. (2023) · Brain · doi:10.1093/brain/awad421 · Cited by 13
Almuslehi, M. S. M., Sen, M. K., Shortland, P. J., Mahns, D. A., & Coorssen, J. R. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-01997-w · Cited by 12
Therapeutic potential of IL-27 in multiple sclerosis?
Fitzgerald, D. C., & Rostami, A. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802646936 · Cited by 12
Kashani, I. R., Hedayatpour, A., Pasbakhsh, P., Kafami, L., Khallaghi, B., & Malek, F. (2015) · Europe PMC (PubMed Central) · Cited by 12
Eltahry, H., Marei, H. E. S., Shams, A., El-Shahat, M., Abdalla, H. A., & El‐kader, M. A. (2016) · Tissue and Cell · doi:10.1016/j.tice.2016.03.001 · Cited by 12
Zhu, X., Yao, Y., Yang, J., Zhang, C., Li, X., Zhang, A., Liu, X., Zhang, C., & Gan, G. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.001 · Cited by 13
Animal Models for the Study of Multiple Sclerosis
Miller, R. H., Fyffe-Maricich, S. L., & Caprariello, A. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00037-1 · Cited by 12
Acute but not inherited demyelination in mouse models leads to brain tissue stiffness changesPreprint
Eberle, D., Fodelianaki, G., Kurth, T., Jagielska, A., Möllmert, S., Ulbricht, E., Wagner, K., Taubenberger, A. V., Träber, N., Escolano, J.-C., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/449603 · Cited by 12
Brain Stiffness Follows Cuprizone-Induced Variations in Local Myelin Content
Zhang, X., & Weickenmeier, J. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.08.033 · Cited by 11
Modulation of OPC Mitochondrial Function by Inhibiting USP30 Promotes Their Differentiation
Soung, A., Kyauk, R. V., Pandey, S., Shen, Y. A., Reichelt, M., Lin, H., Jiang, Z., Kirshnamoorthy, P., Foreman, O., Lauffer, B. E. L., et al. (2024) · Glia · doi:10.1002/glia.24648 · Cited by 11
Diverse Gene Expressions in the Prediction of Cuprizone-Induced Demyelination
Han, S. R., Kang, Y. H., Yoo, S., Lee, M., & Lee, S. (2020) · Neurotoxicity Research · doi:10.1007/s12640-019-00154-3 · Cited by 11
Abe, H., Tanaka, T., Kimura, M., Mizukami, S., Imatanaka, N., Akahori, Y., Yoshida, T., & Shibutani, M. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.01.022 · Cited by 11
Cao, J. H., Hu, Y., Shazeeb, M. S., Pedraza, C. E., Pande, N., Weinstock, D., Polites, G. H., Zhang, W., Chandross, K. J., & Ying, X. (2018) · ASN NEURO · doi:10.1177/1759091418777329 · Cited by 10
Neurotoxicity of Cuprizone in Female and Male Rats: Electrophysiological Observations
Ünsal, C., & Özcan, M. (2018) · Neurophysiology · doi:10.1007/s11062-018-9724-4 · Cited by 12
The K2P‐channel TASK1 affects Oligodendroglial differentiation but not myelin restoration
Albrecht, S., Korr, S., Nowack, L., Narayanan, V., Starost, L. J., Stortz, F., Araúzo-Bravo, M. J., Meuth, S. G., Kuhlmann, T., & Hundehege, P. (2019) · Glia · doi:10.1002/glia.23577 · Cited by 12
Lee, D.-W., Kwon, J.-I., Woo, C.-W., Heo, H., Kim, K. W., Woo, D.-C., Kim, J. K., & Lee, D.-H. (2020) · Diagnostics · doi:10.3390/diagnostics11010045 · Cited by 11
Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice
Mueller, A. M., Nassery, A., Conlon, H., Liu, X., Jun, E., Yoon, B. H., Cristofanilli, M., & Sadiq, S. A. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00034 · Cited by 11
Pericytes in Multiple Sclerosis
Rivera, F. J., Hinrichsen, B., & Silva, M. E. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16908-4_8 · Cited by 11
Generation and potential biomedical applications of embryonic stem cell-derived glial precursors
Glaser, T., Schmandt, T., & Brüstle, O. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.09.018 · Cited by 11
Antiretroviral treatment reveals a novel role for lysosomes in oligodendrocyte maturation
Festa, L. K., Clyde, A. E., Long, C. C., Roth, L. M., Grinspan, J. B., & Jordan‐Sciutto, K. L. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15773 · Cited by 10
ANGPTL2 binds MAG to efficiently enhance oligodendrocyte differentiation
Chen, L., Yu, Z., Xie, L., He, X., Mu, X., Chen, C., Yang, W., Tong, X., Liu, J., Gao, Z., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00970-3 · Cited by 9
Epilepsy and demyelination: Towards a bidirectional relationship
Li, J., Qi, H., Chen, Y., & Zhu, X. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102588 · Cited by 10
Using magnetic resonance imaging in animal models to guide drug development in multiple sclerosis
Nathoo, N., Yong, V. W., & Dunn, J. F. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513512709 · Cited by 10
Kurschus, F. C., Wörtge, S., & Waisman, A. (2011) · Advances in immunology · doi:10.1016/b978-0-12-387663-8.00001-6 · Cited by 10
Proteomic changes during experimental de- and remyelination in the corpus callosum
Szilagyi, G. T., Nawrocki, A. M., Eros, K., Schmidt, J., Fekete, K., Elkjaer, M. L., Hyrlov, K. H., Larsen, M. R., Illes, Z., & Gallyas, F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230249 · Cited by 8
Schoonover, K. E., Farmer, C. B., Morgan, C. J., Sinha, V., Odom, L. B., & Roberts, R. C. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.016 · Cited by 10
Avşar, T., Erdem, G. Ç., Terzioğlu, G., & Turanlı, E. T. (2021) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2104-88 · Cited by 12
Sobel, R. A., Albertelli, M. A., Hinojoza, J. R., Eaton, M. J., Grimes, K., & Rubenstein, E. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac028 · Cited by 10
Yamanaka, K., Nakamura, K., Shibahara, T., Takashima, M., Takaki, H., Hidaka, M., Komori, M., Yoshikawa, Y., Wakisaka, Y., Ago, T., et al. (2022) · Glia · doi:10.1002/glia.24292 · Cited by 10
Wang, X., Wei, Y., Liu, X., Chen, X., Han, G., Chen, G., Hou, C., Dambuza, I. M., Shen, B., Li, Y., et al. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.021 · Cited by 10
Autofluorescence spectroscopy as a proxy for chronic white matter pathology
Morgan, M. L., Kaushik, D. K., Stys, P. K., & Caprariello, A. V. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520948221 · Cited by 10
Lee, J., Villarreal, O. D., Wang, Y. C., Ragoussis, J., Rivest, S., Gosselin, D., & Richard, S. (2022) · Life Science Alliance · doi:10.26508/lsa.202201467 · Cited by 10
Rossi, E. G., Marenna, S., Castoldi, V., Comı, G., & Leocani, L. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114972 · Cited by 9
Nakajima, M., Kawamura, T., Tokui, R., Furuta, K., Sugino, M., Nakanishi, M., Okuyama, S., & Furukawa, Y. (2013) · Brain Research · doi:10.1016/j.brainres.2013.09.024 · Cited by 9
Field, A. S., Samsonov, A. A., Alexander, A. L., Mossahebi, P., & Duncan, I. D. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26300 · Cited by 9
Copper chelation and autoimmunity differentially impact myelin in the hippocampal-prefrontal circuit
Nickel, M., Eid, F., Jukkola, P. I., & Gu, C. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.576998 · Cited by 10
Hahn, K. R., Kim, W., Jung, H. Y., Kwon, H. J., Kim, D. W., Hwang, I. K., & Yoon, Y. S. (2022) · Neurochemical Research · doi:10.1007/s11064-021-03506-8 · Cited by 9
Martinović, K., Bauer, J., Kunze, M., Berger, J., & Forss‐Petter, S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01595-w · Cited by 10
Epigenetic control of myelin repair
Popko, B. (2008) · Nature Neuroscience · doi:10.1038/nn0908-987 · Cited by 9
Davidson, N. L., Yu, F., Kijpaisalratana, N., Le, T. Q., Beer, L. A., Radomski, K. L., & Armstrong, R. C. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24083 · Cited by 9
Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects
Dietrich, M., Aktaş, O., Hartung, H., & Albrecht, P. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000675 · Cited by 9
Yang, H.-J., Wang, L., Cheng, Q. S., & Xu, H. (2011) · Schizophrenia Research and Treatment · doi:10.1155/2011/542896 · Cited by 9
Landzhov, B. V., Gaydarski, L., Stanchev, S., Kostadinova, I., Iliev, A. A., Kotov, G. N., Rashev, P., Mourdjeva, M., Pupaki, D. V., & Stamenov, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313011 · Cited by 9
Serneels, P., Schutter, J. D. D., Groef, L. D., Moons, L., & Bergmans, S. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00694 · Cited by 9
Hahn, K. R., Hwang, I. K., & Yoo, D. Y. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04441-8 · Cited by 8
Soustelle, L., Antal, M. C., Lamy, J., Harsan, L. A., & de Sousa, P. L. (2020) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28397 · Cited by 8
Tenascins Interfere With Remyelination in an Ex Vivo Cerebellar Explant Model of Demyelination
Bauch, J., Ort, S. V., Ulc, A., & Faissner, A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.819967 · Cited by 8
Mapping the Literature on Diet and Multiple Sclerosis: A Data-Driven Approach
Qu, X., Walsh, E., Cherbuin, N., & Black, L. J. (2022) · Nutrients · doi:10.3390/nu14224820 · Cited by 8
Yamazaki, R., & Ohno, N. (2024) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.24-00005 · Cited by 8
Blanke, N., Gray, A. J., Robinson, R. E., Novoseltseva, A., Rosene, D. L., & Bigio, I. J. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00186 · Cited by 8
Partridge, M. A., Myers, S. J., Gopinath, S., & Coorssen, J. R. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400141 · Cited by 8
MedXercise: a promising strategy to promote remyelination
Wuerch, E. C., Lozinski, B. M., & Yong, V. W. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.006 · Cited by 8
Mather, M. L., Jeffries, M. A., & Wood, T. L. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102193 · Cited by 8
Ghobadi, M., Arji, B., Yadegari, M., Esmailidehaj, M., Moghadam, F. H., & Rezvani, M. E. (2022) · PubMed Central · doi:10.22074/cellj.2022.8261 · Cited by 8
Metadata
- Authors
- Matsushima, G. K., & Morell, P.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Matsushima, Glenn K.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2001-01
- Volume
- 11
- Issue
- 1
- Pages
- 107-116
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- PMC
- PMC8098267
- OpenAlex
- W2100904149
- Cited by
- 984
- References
- 45
- Citations by year
- 2026: 31 · 2025: 38 · 2024: 42 · 2023: 50 · 2022: 58 · 2021: 48 · 2020: 55 · 2019: 75 · 2018: 59 · 2017: 65 · 2016: 39 · 2015: 58 · 2014: 39 · 2013: 53 · 2012: 40
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ns011615-29, 5r01ns037815-05, 5r29ns035372-05)
- National Institute of Neurological Disorders and Stroke (NS37815, NS-11615, NS-35372)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cuprizone, demyelination, remyelination, oligodendrocyte apoptosis, microglia, myelin phagocytosis, oligodendrocyte precursor cells, myelin gene expression, C57BL/6 mice, copper chelators
- MeSH terms
- Animals, Central Nervous System, Chelating Agents, Cuprizone, Demyelinating Diseases, Mice, Inbred C57BL, Myelin Sheath, Oligodendroglia, Microglia, Models, Animal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
